LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 34

Search options

  1. Article ; Online: In vitro fosfomycin study on concordance of susceptibility testing methods against ESBL and carbapenem-resistant Enterobacteriaceae.

    Aprile, Ausilia / Scalia, Guido / Stefani, Stefania / Mezzatesta, Maria Lina

    Journal of global antimicrobial resistance

    2020  Volume 23, Page(s) 286–289

    Abstract: Objectives: The increasing emergence and diffusion of multidrug-resistant (MDR) pathogenic bacteria, both in hospital and community settings, is inducing clinicians to reconsider old antibiotics, such as fosfomycin, to overcome the difficulties posed by ...

    Abstract Objectives: The increasing emergence and diffusion of multidrug-resistant (MDR) pathogenic bacteria, both in hospital and community settings, is inducing clinicians to reconsider old antibiotics, such as fosfomycin, to overcome the difficulties posed by these microorganisms. Recent studies have reported good in vitro activity of fosfomycin against extended spectrum ß-lactamases (ESBL) and carbapenem-resistant Enterobacteriaceae. The aim of this study was to assess thein vitro activity of fosfomycin by different methods against 120 clinical MDR isolates.
    Methods: Fosfomycin minimum inhibitory concentrations were determined using the agar dilution reference method (AD), gradient test (GT), broth microdilution method (BMD), according to CLSI recommendations, and automated systems (VITEK 2 and BD Phoenix) against 85 carbapenem-resistant Klebsiella pneumoniae and 35 ESBL-producing Escherichia coli. Agreement and discrepancies between the evaluated methods and the reference method were calculated.
    Results: Fosfomycin showed very good activity against ESBL-producing E. coli (88.6%). Excellent agreement (100%) between the three (AD, BMD and GT) susceptibility methods was found for E. coli. No major errors were observed. The fosfomycin resistance rate ranged from 24% (KPC-producing) to 100% (NDM-OXA-48 co-producing) K. pneumoniae. For all carbapenem-resistant K. pneumoniae strains, categorical agreement was >90% for all methods except for VITEK 2, which was 84%.
    Conclusions: When ESBL E. coli isolates are found to be susceptible to fosfomycin with automated systems, it is not necessary to verify these results with the AD reference method; while for resistant strains, the GT can be used. In cases of KPC K. pneumoniae resistant to fosfomycin, the AD method is the only reference method.
    MeSH term(s) Carbapenem-Resistant Enterobacteriaceae ; Escherichia coli ; Fosfomycin/pharmacology ; Klebsiella pneumoniae ; Microbial Sensitivity Tests
    Chemical Substances Fosfomycin (2N81MY12TE)
    Language English
    Publishing date 2020-10-09
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 2710046-7
    ISSN 2213-7173 ; 2213-7165
    ISSN (online) 2213-7173
    ISSN 2213-7165
    DOI 10.1016/j.jgar.2020.09.022
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Omic insights into various ceftazidime-avibactam-resistant

    Bongiorno, Dafne / Bivona, Dalida A / Cicino, Claudia / Trecarichi, Enrico M / Russo, Alessandro / Marascio, Nadia / Mezzatesta, Maria Lina / Musso, Nicolò / Privitera, Grete F / Quirino, Angela / Scarlata, Giuseppe G M / Matera, Giovanni / Torti, Carlo / Stefani, Stefania

    Frontiers in cellular and infection microbiology

    2023  Volume 12, Page(s) 1010979

    Abstract: Ceftazidime-avibactam (CZA) is one of the best therapeutic options available for infections caused ... ...

    Abstract Ceftazidime-avibactam (CZA) is one of the best therapeutic options available for infections caused by
    MeSH term(s) Humans ; Anti-Bacterial Agents/pharmacology ; Bacterial Proteins/genetics ; Bacterial Proteins/metabolism ; beta-Lactamases/genetics ; beta-Lactamases/metabolism ; Ceftazidime/pharmacology ; Drug Combinations ; Klebsiella Infections/microbiology ; Klebsiella pneumoniae/drug effects ; Klebsiella pneumoniae/isolation & purification ; Meropenem ; Drug Resistance, Multiple, Bacterial
    Chemical Substances Anti-Bacterial Agents ; avibactam, ceftazidime drug combination ; Bacterial Proteins ; beta-Lactamases (EC 3.5.2.6) ; Ceftazidime (9M416Z9QNR) ; Drug Combinations ; Meropenem (FV9J3JU8B1)
    Language English
    Publishing date 2023-01-05
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2619676-1
    ISSN 2235-2988 ; 2235-2988
    ISSN (online) 2235-2988
    ISSN 2235-2988
    DOI 10.3389/fcimb.2022.1010979
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Overview of the Clinical and Molecular Features of Legionella Pneumophila: Focus on Novel Surveillance and Diagnostic Strategies.

    Gattuso, Giuseppe / Rizzo, Roberta / Lavoro, Alessandro / Spoto, Vincenzoleo / Porciello, Giuseppe / Montagnese, Concetta / Cinà, Diana / Cosentino, Alessia / Lombardo, Cinzia / Mezzatesta, Maria Lina / Salmeri, Mario

    Antibiotics (Basel, Switzerland)

    2022  Volume 11, Issue 3

    Abstract: Legionella ... ...

    Abstract Legionella pneumophila
    Language English
    Publishing date 2022-03-09
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2681345-2
    ISSN 2079-6382
    ISSN 2079-6382
    DOI 10.3390/antibiotics11030370
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: In vitro evidence of the synergistic interaction of ceftopibrole and other antibiotics against multidrug-resistant Gram-negative isolates.

    Aprile, Ausilia / Caio, Carla / Gona, Floriana / Stefani, Stefania / Mezzatesta, Maria Lina

    Diagnostic microbiology and infectious disease

    2019  Volume 95, Issue 4, Page(s) 114884

    Abstract: The purpose of the present study was to investigate the in vitro activity of ceftobiprole in combination with other antimicrobials against 27 selected Gram-negative isolates, including ESBL-producing E. coli and KPC-OXA-48-producing K. pneumoniae. ... ...

    Abstract The purpose of the present study was to investigate the in vitro activity of ceftobiprole in combination with other antimicrobials against 27 selected Gram-negative isolates, including ESBL-producing E. coli and KPC-OXA-48-producing K. pneumoniae. Ceftobiprole activity in combination with amikacin, colistin, levofloxacin, piperacillin/tazobactam and rifampin was evaluated by time-kill curves and gradient-cross method (except colistin). Among the 27 strains tested with gradient strips most were resistant to ceftobiprole. Synergy was observed in some cases with piperacillin/tazobactam. There was at least one synergistic combination towards 9 isolates belonging to different species. No antagonism was observed with any of the antibiotic tested. In time-kill curves, performed for 12 selected isolates, synergistic interaction was more frequent, occurring with 32/60 combinations. The most interesting results of our study are the bactericidal effects of ceftobiprole in combination with colistin or piperacillin/tazobactam tested against Gram-negative isolates, including KPC and OXA-48-producing K. pneumoniae.
    MeSH term(s) Anti-Bacterial Agents/pharmacology ; Cephalosporins/pharmacology ; Drug Resistance, Multiple, Bacterial/drug effects ; Drug Synergism ; Gram-Negative Bacteria/drug effects ; Gram-Negative Bacteria/enzymology ; Gram-Negative Bacteria/isolation & purification ; Gram-Negative Bacterial Infections/microbiology ; Humans ; Microbial Sensitivity Tests ; Microbial Viability/drug effects ; beta-Lactamases/metabolism
    Chemical Substances Anti-Bacterial Agents ; Cephalosporins ; ceftobiprole (5T97333YZK) ; beta-Lactamases (EC 3.5.2.6)
    Language English
    Publishing date 2019-08-07
    Publishing country United States
    Document type Journal Article
    ZDB-ID 604920-5
    ISSN 1879-0070 ; 0732-8893
    ISSN (online) 1879-0070
    ISSN 0732-8893
    DOI 10.1016/j.diagmicrobio.2019.114884
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: In Vitro Activity of Sulbactam-Durlobactam against Carbapenem-Resistant

    Segatore, Bernardetta / Piccirilli, Alessandra / Cherubini, Sabrina / Principe, Luigi / Alloggia, Giovanni / Mezzatesta, Maria Lina / Salmeri, Mario / Di Bella, Stefano / Migliavacca, Roberta / Piazza, Aurora / Meroni, Elisa / Fazii, Paolo / Visaggio, Daniela / Visca, Paolo / Cortazzo, Venere / De Angelis, Giulia / Pompilio, Arianna / Perilli, Mariagrazia

    Antibiotics (Basel, Switzerland)

    2022  Volume 11, Issue 8

    Abstract: In the present study, the in vitro activity of the sulbactam-durlobactam (SUL-DUR) combination was evaluated against 141 carbapenem- ... ...

    Abstract In the present study, the in vitro activity of the sulbactam-durlobactam (SUL-DUR) combination was evaluated against 141 carbapenem-resistant
    Language English
    Publishing date 2022-08-22
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2681345-2
    ISSN 2079-6382
    ISSN 2079-6382
    DOI 10.3390/antibiotics11081136
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Extensively drug-resistant ArmA-producing Acinetobacter baumannii in an Italian intensive care unit.

    Caio, Carla / Maugeri, Gaetano / Zingali, Tiziana / Gona, Floriana / Stefani, Stefania / Mezzatesta, Maria Lina

    The new microbiologica

    2018  Volume 41, Issue 2, Page(s) 159–161

    Abstract: We describe the spread of 12 carbapenem-resistant Acinetobacter baumannii isolates in hospitalized patients. All strains showed an extensively drug-resistant phenotype and high-level of aminoglycoside resistance, harboring the ArmA gene and blaoxa-23 ... ...

    Abstract We describe the spread of 12 carbapenem-resistant Acinetobacter baumannii isolates in hospitalized patients. All strains showed an extensively drug-resistant phenotype and high-level of aminoglycoside resistance, harboring the ArmA gene and blaoxa-23 downstream of ISAba1 (transposon Tn2008 arrangement) where both were located on the chromosome. These strains carry a class 1 integron containing the gene cassette aacA4-catB8-aadA1. Molecular analysis revealed that all isolates belonged to the same sequence type (ST) 2 clone. The spread of ArmA-producing A. baumannii strains limit the treatment options showing the dramatic situation which requires novel therapies to limit high mortality rates.
    MeSH term(s) Acinetobacter Infections/microbiology ; Acinetobacter baumannii/drug effects ; Acinetobacter baumannii/genetics ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Bacterial Proteins/genetics ; Bacterial Proteins/metabolism ; Carbapenems/pharmacology ; Cross Infection/microbiology ; Drug Resistance, Multiple, Bacterial/genetics ; Humans ; Intensive Care Units ; Italy/epidemiology ; Microbial Sensitivity Tests
    Chemical Substances Anti-Bacterial Agents ; Bacterial Proteins ; Carbapenems
    Language English
    Publishing date 2018-04
    Publishing country Italy
    Document type Journal Article
    ZDB-ID 756168-4
    ISSN 1121-7138 ; 0391-5352
    ISSN 1121-7138 ; 0391-5352
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Colistin Resistant

    Cafiso, Viviana / Stracquadanio, Stefano / Lo Verde, Flavia / Gabriele, Giacoma / Mezzatesta, Maria Lina / Caio, Carla / Pigola, Giuseppe / Ferro, Alfredo / Stefani, Stefania

    Frontiers in microbiology

    2019  Volume 9, Page(s) 3195

    Abstract: Even though colistin-based treatment represents the antimicrobial-regimen backbone for the management of multidrug-resistant Gram-negative infections, colistin resistance is still rare, at least as a full resistance, ... ...

    Abstract Even though colistin-based treatment represents the antimicrobial-regimen backbone for the management of multidrug-resistant Gram-negative infections, colistin resistance is still rare, at least as a full resistance, in
    Language English
    Publishing date 2019-01-07
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2587354-4
    ISSN 1664-302X
    ISSN 1664-302X
    DOI 10.3389/fmicb.2018.03195
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Combination of aztreonam, ceftazidime-avibactam and amikacin in the treatment of VIM-1 Pseudomonas aeruginosa ST235 osteomyelitis.

    Mularoni, Alessandra / Mezzatesta, Maria Lina / Pilato, Michele / Medaglia, Alice Annalisa / Cervo, Adriana / Bongiorno, Dafne / Aprile, Ausilia / Luca, Angelo / Stefani, Stefania / Grossi, Paolo

    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

    2021  Volume 108, Page(s) 510–512

    Abstract: We describe a challenging case of patient with metallo-beta-lactamase-producing Pseudomonas aeruginosa sternal osteomyelitis following aortic valve replacement with biological prosthesis. The strain exhibited a multidrug-resistance phenotype carrying the ...

    Abstract We describe a challenging case of patient with metallo-beta-lactamase-producing Pseudomonas aeruginosa sternal osteomyelitis following aortic valve replacement with biological prosthesis. The strain exhibited a multidrug-resistance phenotype carrying the bla
    MeSH term(s) Aged ; Amikacin/therapeutic use ; Anti-Bacterial Agents/therapeutic use ; Azabicyclo Compounds/therapeutic use ; Aztreonam/therapeutic use ; Ceftazidime/therapeutic use ; Debridement ; Drug Combinations ; Drug Resistance, Multiple, Bacterial/genetics ; Drug Therapy, Combination ; Female ; Humans ; Osteomyelitis/drug therapy ; Osteomyelitis/microbiology ; Osteomyelitis/surgery ; Pseudomonas Infections/drug therapy ; Pseudomonas Infections/surgery ; Pseudomonas aeruginosa
    Chemical Substances Anti-Bacterial Agents ; Azabicyclo Compounds ; Drug Combinations ; avibactam, ceftazidime drug combination ; Amikacin (84319SGC3C) ; Ceftazidime (9M416Z9QNR) ; Aztreonam (G2B4VE5GH8)
    Language English
    Publishing date 2021-06-04
    Publishing country Canada
    Document type Case Reports
    ZDB-ID 1331197-9
    ISSN 1878-3511 ; 1201-9712
    ISSN (online) 1878-3511
    ISSN 1201-9712
    DOI 10.1016/j.ijid.2021.05.085
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Emergence of two novel sequence types (3366 and 3367) NDM-1- and OXA-48-co-producing K. pneumoniae in Italy.

    Gona, Floriana / Bongiorno, Dafne / Aprile, Ausilia / Corazza, Erika / Pasqua, Betta / Scuderi, Maria Grazia / Chiacchiaretta, Matteo / Cirillo, Daniela Maria / Stefani, Stefania / Mezzatesta, Maria Lina

    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology

    2019  Volume 38, Issue 9, Page(s) 1687–1691

    Abstract: The aim of this study was to analyze the alarming spread of NDM-1- and OXA-48-co-producing Klebsiella pneumoniae clinical isolates, collected between October 2016 and January 2018 in a neonatal intensive care unit of the University Hospital, Catania, ... ...

    Abstract The aim of this study was to analyze the alarming spread of NDM-1- and OXA-48-co-producing Klebsiella pneumoniae clinical isolates, collected between October 2016 and January 2018 in a neonatal intensive care unit of the University Hospital, Catania, Italy, through whole genome sequencing. All confirmed carbapenem-resistant K. pneumoniae (CRKp) isolates were characterized pheno- and geno-typically, as well as by whole genome sequencing (WGS). A total of 13 CRKp isolates were identified from 13 patients. Pulsed-field gel electrophoresis (PFGE) was performed, and the multilocus sequence typing (MLST) scheme used was based on the gene sequence as published on the MLST Pasteur website. Core genome MLST (cgMLST) was also performed. All isolates co-carried bla
    MeSH term(s) Anti-Bacterial Agents/pharmacology ; Bacterial Proteins/genetics ; Bacterial Typing Techniques ; Carbapenems/pharmacology ; Disease Outbreaks ; Electrophoresis, Gel, Pulsed-Field ; Humans ; Infant, Newborn ; Intensive Care, Neonatal ; Italy ; Klebsiella Infections/microbiology ; Klebsiella pneumoniae/drug effects ; Klebsiella pneumoniae/enzymology ; Klebsiella pneumoniae/genetics ; Microbial Sensitivity Tests ; Multilocus Sequence Typing ; Whole Genome Sequencing ; beta-Lactamases/genetics
    Chemical Substances Anti-Bacterial Agents ; Bacterial Proteins ; Carbapenems ; beta-Lactamases (EC 3.5.2.6) ; beta-lactamase NDM-1 (EC 3.5.2.6) ; oxacillinase (EC 3.5.2.6)
    Language English
    Publishing date 2019-06-05
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 603155-9
    ISSN 1435-4373 ; 0934-9723 ; 0722-2211
    ISSN (online) 1435-4373
    ISSN 0934-9723 ; 0722-2211
    DOI 10.1007/s10096-019-03597-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Enterobacter cloacae complex: clinical impact and emerging antibiotic resistance.

    Mezzatesta, Maria Lina / Gona, Floriana / Stefani, Stefania

    Future microbiology

    2012  Volume 7, Issue 7, Page(s) 887–902

    Abstract: Species of the Enterobacter cloacae complex are widely encountered in nature, but they can act as pathogens. The biochemical and molecular studies on E. cloacae have shown genomic heterogeneity, comprising six species: Enterobacter cloacae, Enterobacter ... ...

    Abstract Species of the Enterobacter cloacae complex are widely encountered in nature, but they can act as pathogens. The biochemical and molecular studies on E. cloacae have shown genomic heterogeneity, comprising six species: Enterobacter cloacae, Enterobacter asburiae, Enterobacter hormaechei, Enterobacter kobei, Enterobacter ludwigii and Enterobacter nimipressuralis, E. cloacae and E. hormaechei are the most frequently isolated in human clinical specimens. Phenotypic identification of all species belonging to this taxon is usually difficult and not always reliable; therefore, molecular methods are often used. Although the E. cloacae complex strains are among the most common Enterobacter spp. causing nosocomial bloodstream infections in the last decade, little is known about their virulence-associated properties. By contrast, much has been published on the antibiotic-resistance features of these microorganisms. In fact, they are capable of overproducing AmpC β-lactamases by derepression of a chromosomal gene or by the acquisition of a transferable ampC gene on plasmids conferring the antibiotic resistance. Many other resistance determinants that are able to render ineffective almost all antibiotic families have been recently acquired. Most studies on antimicrobial susceptibility are focused on E. cloacae, E. hormaechei and E. asburiae; these studies reported small variations between the species, and the only significant differences had no discriminating features.
    MeSH term(s) Bacterial Proteins/metabolism ; Cross Infection/epidemiology ; Cross Infection/microbiology ; Drug Resistance, Bacterial ; Enterobacter/drug effects ; Enterobacter/genetics ; Enterobacter/isolation & purification ; Enterobacter/pathogenicity ; Enterobacter cloacae/drug effects ; Enterobacter cloacae/genetics ; Enterobacter cloacae/isolation & purification ; Enterobacter cloacae/pathogenicity ; Enterobacteriaceae Infections/epidemiology ; Enterobacteriaceae Infections/microbiology ; Humans ; Molecular Typing ; beta-Lactamases/metabolism
    Chemical Substances Bacterial Proteins ; AmpC beta-lactamases (EC 3.5.2.6) ; beta-Lactamases (EC 3.5.2.6)
    Language English
    Publishing date 2012-07
    Publishing country England
    Document type Journal Article ; Review
    ISSN 1746-0921
    ISSN (online) 1746-0921
    DOI 10.2217/fmb.12.61
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top